A prospective survey on incidence and outcome of Broviac/Hickman catheter-related complications in pediatric patients affected by hematological and oncological diseases

被引:68
作者
Cesaro, S
Corrò, R
Pelosin, A
Gamba, P
Zadra, N
Fusaro, F
Pillon, M
Cusinato, R
Zampieri, C
Magagna, L
Cavaliere, M
Tridello, G
Zanon, G
Zanesco, L
机构
[1] Univ Padua, Clin Pediat Hematol Oncol, Dept Pediat, I-35128 Padua, Italy
[2] Univ Padua, Dept Pediat, Div Pediat Surg, Padua, Italy
[3] Univ Padua, Serv Pediat, Inst Anesthesiol, Padua, Italy
[4] Univ Padua, Inst Microbiol & Virol, Microbiol Serv, Padua, Italy
关键词
Broviac/Hickman central venous catheter; complications; infections; pediatric malignancy;
D O I
10.1007/s00277-003-0796-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A prospective pediatric survey on the incidence of central venous catheter (CVC) complications was performed aimed at identifying risk factors of premature CVC removal. The study comprised 129 Broviac-Hickman CVCs inserted during a 13-month period in 112 children. The total number of CVC days was 19,328 (median: 122 days, range: 1-385). The overall rate of complications was 6.2/1000 CVC days, i.e., 4.5/1000 and 1.7/1000 CVC days for mechanical and infectious complications, respectively. Interestingly, only two CVC-related cases of septicemia and no thrombotic events were documented. At the end of the study period, 38 of 129 CVC (29.5%) had been removed: 20 due to CVC-related complications (dislocation18, rupture 2), 10 due to the patient's death, and 8 due to completion of therapy. Age at CVC insertion <4.9 years was a significant predictor of premature CVC removal (p=0.01). Mechanical complications, especially in younger children, are the main cause of premature loss of CVC. These data underline the importance of more effectively securing the CVC to subcutaneous tissue in pediatric patients to reduce accidental dislocations.
引用
收藏
页码:183 / 188
页数:6
相关论文
共 26 条
[1]   Guidelines for antithrombotic therapy in pediatric patients [J].
Andrew, M ;
Michelson, AD ;
Bovill, E ;
Leaker, M ;
Massicotte, MP .
JOURNAL OF PEDIATRICS, 1998, 132 (04) :575-588
[2]   Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies [J].
Boraks, P ;
Seale, J ;
Price, J ;
Bass, G ;
Ethell, M ;
Keeling, D ;
Mahendra, P ;
Baglin, T ;
Marcus, R .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (03) :483-486
[3]   The antibiotic-lock technique for therapy of 'highly needed' infected catheters [J].
Carratalà, J .
CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (05) :282-289
[4]   Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters [J].
Chesler, L ;
Feusner, JH .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (08) :653-656
[5]  
Daghistani D, 1996, MED PEDIATR ONCOL, V26, P405, DOI 10.1002/(SICI)1096-911X(199606)26:6<405::AID-MPO6>3.3.CO
[6]  
2-K
[7]   Clinical management of catheter-related infections [J].
Fätkenheuer, G ;
Cornely, O ;
Seifert, H .
CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (09) :545-550
[8]   Prospective study of indwelling central venous catheter-related complications in children with broviac or clampless valved catheters [J].
Fratino, G ;
Molinari, AC ;
Mazzola, C ;
Giacchino, M ;
Saracco, P ;
Bertocchi, E ;
Castagnola, E .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (08) :657-661
[9]   Indications and complications of intravenous devices for chemotherapy [J].
Freytes, CO .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (04) :303-307
[10]  
Germanakis I, 2002, HAEMA, V5, P297